PUBLISHER: 360iResearch | PRODUCT CODE: 1470428
PUBLISHER: 360iResearch | PRODUCT CODE: 1470428
[189 Pages Report] The Cardiac Marker Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.16 billion in 2024, at a CAGR 9.71% to reach USD 7.29 billion by 2030.
Cardiac markers are substances or molecules measured in the blood to diagnose and monitor various cardiac conditions, particularly those related to heart muscle damage or stress. These markers are often used in clinical settings, such as hospitals and laboratories, to assist in diagnosing, prognosis, and monitoring cardiovascular diseases. They are particularly widely used in the diagnosis of conditions such as myocardial infarction and other forms of acute coronary syndrome. With an increased emphasis on accurate and early diagnosis in cases of cardiovascular diseases (CVD), the cardiac markers market's valuation has been progressively escalating. The rising incidence of cardiovascular conditions and the growing global geriatric population fuel the market demand for cardiac markers. Rising demand for point-of-care testing and the steady development in healthcare infrastructure, including well-equipped labs and trained personnel, globally aids the industry's growth. However, High prices associated with cardiovascular procedures and solutions affect market adoption. The evolution of the biomedical industry, particularly diagnostic technologies, and government healthcare initiatives and programs aiming to foster preventative care are instrumental in escalating the demand for cardiac markers and creating a significant growth opportunity for the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.81 billion |
Estimated Year [2024] | USD 4.16 billion |
Forecast Year [2030] | USD 7.29 billion |
CAGR (%) | 9.71% |
Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins
Chemiluminescence immunoassay (CLIA) systems are sophisticated diagnostic instruments that detect high-sensitivity cardiac markers such as troponin, CK-MB, and myoglobin. These instruments utilize luminogenic substrates that emit light upon reaction with specific enzymes in the presence of the targeted antigen. Enzyme-linked immunosorbent assay (ELISA) kits and instruments are vital in detecting and quantifying cardiac markers. These assays rely on an enzyme-conjugate reaction that produces a measurable colorimetric change. ELISA systems offer flexibility in terms of scalability and are known for their specificity and high sensitivity. Immunochromatography is a rapid and simple diagnostic technique that utilizes the movement of particles along a membrane via capillary action. It involves using antibodies and antigens to detect specific biomarkers, such as cardiac markers. Immunofluorescence is a technique that uses fluorescent dyes or markers to detect the presence of specific antibodies or antigens, and it is employed for more detailed and specific analysis in the context of cardiac markers. Reagents and kits for cardiac marker detection comprise a wide range of immunoassays optimized for various analytical platforms. These consumables often include antibodies, antigens, buffers, and substrates specifically engineered for the qualitative and quantitative assessment of cardiac-specific proteins.
Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure
BNP and NT-proBNP are biomarkers for diagnosing and managing heart failure. BNP is discharged by ventricular myocytes in reaction to increased wall tension, typically due to fluid overload in heart failure. When found at low levels, these peptides have a strong negative predictive value for cardiac risk and heart failure. In contrast, elevated levels are indicative of an increased risk of adverse cardiovascular events. Creatine Kinase-MB (CK-MB) is an isoenzyme of creatine kinase (CK) and is one of the traditional biomarkers for diagnosing myocardial infarction (MI). It is found mainly in cardiac cells and increases in the blood following the death of heart muscle cells. High-sensitivity C-Reactive Protein (Hs-CRP) is an acute-phase protein and a non-specific inflammatory biomarker that can indicate systemic inflammation. It is often used to assess the risk of cardiac disease and other cardiac risk factors. Myoglobin is an early but non-specific marker of myocardial injury. It is most valuable when used alongside more specific cardiac markers, such as troponins, for the early assessment of myocardial infarction. Troponin I and T are regulatory proteins that are part of the cardiac muscle contractile apparatus and are highly specific and sensitive biomarkers for myocardial injury.
End-User: Significant utilization of cardiac marker in laboratory testing facilities
Laboratory testing facilities are typically equipped with sophisticated equipment and skilled personnel capable of performing a comprehensive range of tests. Hospitals and independent diagnostic labs are the primary constituents of this sector. They offer accurate and high-volume cardiac marker testing services, integral for diagnosing various cardiovascular conditions, including myocardial infarctions (heart attacks) and acute coronary syndromes. Point of Care (POC) testing facilities include emergency departments, ambulances, clinics, and physician offices. The immediacy of results allows for swift clinical decision-making, critical in managing cardiac emergencies. POC testing for cardiac markers, such as troponin, BNP (B-type natriuretic peptide), and D-dimer, has revolutionized diagnosing and managing cardiovascular diseases. POCT systems for cardiac markers are designed for simplicity and speed, reducing the turnaround time for decision-making in acute care settings.
Indication: Potential adoption of cardiac markers in congestive heart failure situations
In congestive heart failure (CHF) situations, cardiac markers are crucial in diagnosis, prognosis, and management. B-type natriuretic peptide (BNP) and N-terminal-pro BNP (NT-proBNP) are the primary biomarkers used to confirm suspected CHF, differentiate it from other causes of dyspnea, and assess the severity of the condition. Elevated levels of BNP or NT-proBNP are associated with heart failure, and these markers are used for both diagnosis and monitoring of CHF patients. In myocardial infarction (MI), Troponin I, Troponin T, and creatine kinase-MB (CK-MB) are commonly used cardiac markers for myocardial infarction. Troponins are sensitive and specific markers for detecting myocardial injury. Elevated levels of troponins indicate myocardial infarction and help in diagnosing acute coronary syndrome.
Regional Insights
The Americas has a significant market landscape in the cardiac marker market due to a high prevalence of cardiovascular diseases, well-established healthcare facilities, and major market players. The increasing incidence of heart attacks and the strong focus on early diagnosis and treatment are driving the demand for cardiac marker tests in this region. Moreover, advancements in the biotechnology sector and higher adoption rates for novel diagnostics methodologies contribute to America's cardiac marker market growth. Europe's market growth in the cardiac marker is propelled by the rising aging population, which is more prone to chronic diseases, including coronary heart disease. The availability of cutting-edge healthcare facilities, rising healthcare expenditures, and favorable regulatory policies also support the growth of the European cardiac marker market. Moreover, several key market players and ongoing research activities in the cardiac biomarkers space further stimulate market growth. The Asia-Pacific region is projected to show a significant cardiac marker market growth rate during the forecast period attributed to the large population base, the rising incidences of lifestyle diseases, and the gradual improvement in healthcare infrastructure across emerging economies.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Marker Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Marker Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cardiac Marker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aehealth Limited, Becton, Dickinson and Company, BG Medicine Inc., Bio-Rad Laboratories, Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.P.A., HyTest Ltd., LSI Medience Corporation, PerkinElmer Inc., QuidelOrtho Corporation, Randox Laboratories Ltd., Roche Diagnostics Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Cardiac Marker Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Marker Market?
3. What are the technology trends and regulatory frameworks in the Cardiac Marker Market?
4. What is the market share of the leading vendors in the Cardiac Marker Market?
5. Which modes and strategic moves are suitable for entering the Cardiac Marker Market?